Kura Oncology (NASDAQ:KURA) Stock Price Down 2.7% – Should You Sell?

Kura Oncology, Inc. (NASDAQ:KURA)’s share price traded down 2.7% during mid-day trading on Monday . The company traded as low as $7.69 and last traded at $7.63. 44,364 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,057,173 shares. The stock had previously closed at $7.84.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on KURA shares. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Scotiabank decreased their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. JMP Securities restated a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. UBS Group reduced their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Trading Down 2.9 %

The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a fifty day moving average of $7.82 and a 200 day moving average of $12.38. The firm has a market capitalization of $614.55 million, a PE ratio of -3.22 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. Equities research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,729 shares of company stock valued at $92,307. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Kura Oncology by 7.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock valued at $1,147,000 after purchasing an additional 9,050 shares during the period. Woodline Partners LP boosted its position in shares of Kura Oncology by 20.6% during the fourth quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock worth $1,504,000 after buying an additional 29,497 shares during the period. Velan Capital Investment Management LP bought a new position in Kura Oncology in the 4th quarter worth approximately $1,306,000. Squarepoint Ops LLC acquired a new stake in Kura Oncology in the 4th quarter valued at approximately $799,000. Finally, Two Sigma Advisers LP raised its stake in Kura Oncology by 147.1% during the 4th quarter. Two Sigma Advisers LP now owns 242,200 shares of the company’s stock valued at $2,110,000 after acquiring an additional 144,201 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.